Anagenesis Biotechnologies secures a new investment from Cap Innov’Est

Anagenesis Biotechnologies secures a new investment from Cap Innov’Est


Strasbourg, France - May 19th, 2015 – Anagenesis Biotechnologies, a biotechnology company developing therapies for Duchenne Muscular Dystrophy (DMD) and other muscle diseases, announced the investment of Cap Innov’Est, an interregional-based seed fund. 

This funding will enable Anagenesis Biotechnologies to expand and complete the “Proof of Concept” that targeting the adult muscle stem cells, called satellite cells, is able to regenerate muscle fibers. 

Jean-Yves Bonnefoy, Anagenesis Biotechnologies’ President and CEO, said ‘“I am pleased to see Cap Innov’Est joining the company’s founders following the AFM-Téléthon patient Association. This funding will allow us to advance our product candidates, cell therapy and small molecules, which have a unique competitive advantage over other DMD drug candidates: the potential to restore muscle function in advanced patients, and not just only slowing the course of the disease”. 

Jean-François Rax, Investment Director at Cap Innov’Est, said: “We are truly enthusiastic to invest in such a promising start-up. We are convinced that Anagenesis' breakthrough technology combined with its experienced management team will be successful in bringing innovative and efficient treatments for muscle diseases to the patients, especially those suffering from DMD.” 

Jean-François Rax is joining the Board of Anagenesis Biotechnologies composed of Dr Christopher Henderson, VP, Neurology, Biogen, co-founder of Anagenesis Biotechnologies and Trophos (recently acquired by Roche), Nicolas Carboni, President and CEO of SATT Conectus, Philippe Grand, Partner, Ernst & Young and Dr Jean-Yves Bonnefoy, Chairman.


About Duchenne Muscular Dystrophy 

Duchenne Muscular Dystrophy (DMD) is an X-linked rare degenerative neuromuscular disorder causing severe progressive muscle loss and premature death. One of the most common fatal genetic disorders, DMD affects approximately one in every 3,500 boys born worldwide. A devastating and incurable muscle-wasting disease, DMD is associated with specific errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Progressive muscle weakness in the lower limbs spreads to the arms, neck and other areas. Eventually, increasing difficulty in breathing due to respiratory muscle dysfunction requires ventilation support, and cardiac dysfunction can lead to heart failure. The condition is universally fatal, and death usually occurs before the age of 30.


About Anagenesis Biotechnologies 

Anagenesis Biotechnologies is a company that develops new treatments against muscle diseases (genetic such as DMD and chronic such as sarcopenia and cachexia) which goal is to preserve/give people autonomy, freedom to move, dignity and social life. Our mission is based on a vision shared by all stakeholders at Anagenesis Biotechnologies: to create a world where everyone could – and should – be able to move, every single day of their life. This is the dream and hope on which our project is based – the path is long but the way is known. One of the cofounders of the company is Pr. Olivier Pourquié, a worldwide key opinion leader in the field of musculoskeletal development and stem cells. Olivier is a Professor at Harvard Medical School and member of the Harvard Stem Cell Institute. Pr. Olivier Pourquié and Anagenesis Biotechnologies have both benefited from the long standing support from AFMTéléthon Patient Association. Anagenesis Biotechnologies is backed by a solid, experienced team led by its President & CEO, Dr Jean-Yves Bonnefoy. Jean-Yves comes from the Pharma & biotech industry and brings to the team his experience in the field of pharmaceutical development. For more informations: www.anagenesis-biotech.com


About Cap Innov’Est


Cap Innov’Est is a 36 M€ tri-regional (Alsace, Bourgogne, Franche-Comté) fund dedicated to investments in young innovative start-ups. Cap Innov’Est was launched in July 2014 and has already invested in 6 start-ups.
Cap Innov’Est is supported by Fonds National d’Amorçage, the 3 Regions Alsace, Bourgogne et Franche-Comté, SAFIDI, caisses d’épargne d’Alsace et Bourgogne/Franche-Comté, BNP Paribas & CIFC. For more informations: www.alsacecapital.eu


Contacts : 

 

Anagenesis Biotechnologies

Cap Innov’Est

Jean-Yves Bonnefoy

Jean-François Rax

President & CEO

Investment Manager

jybonnefoy@anagenesis-biotech.com

jfrax@alsacecapital.eu

www.anagenesis-biotech.com

www.alsacecapital.eu

Calendar of events

< April 2018 >
Mon.Tue.Wed.Thu.Fri.Sat.Sun.
1
2
3
4
5
6 7
8
9 10
11
12
13
14
15
16
17
18 19
20
21
22
23
24
25 26
27
28
29
30

They Support FACCNE

    • Albany Engineered
    • Aquto
    • Axelia Partners (former Marie Landel & Associates)
    • BIBSMA
    • Bewell Connect
    • BioMerieux
    • Boston Accueil
    • Boston Strasbourg Sister City Association
    • CM CIC
    • Cisbio
    • DSML Executive Search
    • Dassault Systems
    • Edenred
    • Essilor
    • French Cultural Center
    • French Tech Hub
    • Good Leads
    • Hepatochem
    • Hubbard
    • IdeaPaint
    • Infotraffic system tv
    • Ipsen
    • Jabra
    • Keolis CS
    • MGB US Inc.
    • MIRAKL
    • Magicforest
    • Mauna Kea Technologies
    • Mc Dermott Will & Emery
    • Miltons Distributing
    • Moderna Therapeutics
    • NFI
    • North Shore InnoVentures
    • OpenDataSoft
    • Pact and Partners
    • Paul Frank + Collins P.C.
    • Puma
    • SES America
    • Sanofi Genzyme
    • Schneider Electric
    • Sigfox
    • Socomec
    • Softbank Robotics
    • Spring Technologies
    • Sullivan & Worcester
    • Valti
    • Veolia
    • Vivra
    • Withings
    • World Boston

185 Alewife Brook Parkway, Suite 200 
Cambridge, MA 02138
 T: (617) 520-2121 
 contact(at)faccne.org

Please contact us to schedule an appointment.

 

 

© 2018 FACC NEW ENGLAND